Simplex Trading
ONCT

Simplex Trading’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Simplex Trading’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-435
Closed -$7K – 10818
2022
Q3 		$7K Sell
435
-730
-63% -$15.7K ﹤0.01% 8593
2022
Q2 		$25K Buy
1,165
+325
+39% +$7.25K ﹤0.01% 7366
2022
Q1 		$23K Buy
840
+485
+137% +$17.7K ﹤0.01% 8121
2021
Q4 		$16K Sell
355
-2,000
-85% -$135K ﹤0.01% 8640
2021
Q3 		$224K Hold
2,355
– – ﹤0.01% 5424
2021
Q2 		$223K Buy
2,355
+2,337
+12,983% +$277K ﹤0.01% 5518
2021
Q1 		$295K Buy
18
+17
+1,700% +$2.25K ﹤0.01% 4163
2020
Q4 		$9K Buy
+1
New +$63 ﹤0.01% 7492
2019
Q2 		– Sell
-1
Closed -$11K – 7997
2019
Q1 		$11K Hold
1
– – ﹤0.01% 6125
2018
Q4 		$9K Hold
1
– – ﹤0.01% 5931
2018
Q3 		$20K Buy
+1
New +$2.4K ﹤0.01% 5965
2018
Q2 		– Hold
0
– – – 6966
2018
Q1 		– Hold
0
– – – 4392
2017
Q3 		– Sell
-1
Closed -$34K – 6840
2017
Q2 		$34K Buy
+1
New +$613 ﹤0.01% 2771
2017
Q1 		– Hold
0
– – – 5858

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $324M AUM 37.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Simplex Trading's ONCT Position: Q2 2023 in Review

Simplex Trading sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q2 2023, closing a stake of 356 shares — an estimated $5K sold.

Simplex Trading first reported a position in ONCT in Q4 2014 and held it in 17 quarters. The position peaked at $319K in Q1 2021. 52 funds tracked by Wall St. Rank hold ONCT as of Q2 2023.

  • Simplex Trading reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Simplex Trading sold 356 Oncternal Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $5K.
  • Simplex Trading first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2014 and held it in 17 quarters.
  • Simplex Trading's Oncternal Therapeutics, Inc. Common Stock position peaked at $319K in Q1 2021.
  • 52 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Simplex Trading's 13F filing for Q2 2023, filed 4 Aug 2023.